<DOC>
	<DOC>NCT02795182</DOC>
	<brief_summary>This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in subjects with B-cell lymphoid malignancies.</brief_summary>
	<brief_title>BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies</brief_title>
	<detailed_description />
	<criteria>Aged ≥ 18 years, able and willing to provide written informed consent and to comply with the study protocol. Laboratory parameters as specified below: Hematologic: platelet count &gt; 50 x 10e9/L; absolute neutrophil count &gt; 1.0 x109 cells/L; Hepatic: total Bilirubin ≤ 1.5 times the upper limit of normal (ULN) ; and aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ≤ 3x ULN Renal: creatinine clearance ≥ 30 mL/min ; subjects requiring hemodialysis will be excluded. Anticipated survival of at least 4 months Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Female subjects of childbearing potential and nonsterile males must practice at least one of the following methods of birth control with partner(s) throughout the study and for ≥ 3 months after discontinuing study drugs: total abstinence from sexual intercourse, doublebarrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drugs. Male subjects must not donate sperm from initial study drug administration, until 180 days after drug discontinuation. Known, active, central nervous system lymphoma or leukemia Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura History of stroke or cerebral hemorrhage within 6 months of enrollment History of significant cardiovascular disease, defined as: Congestive heart failure greater than New York Heart Association (NYHA) class II according to the NYHA functional classification Unstable angina or myocardial infarction with 6 months of enrollment Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, congestive obstructive pulmonary disease) History of severe allergic or anaphylactic reactions to monoclonal antibody therapy Prior Bruton's tyrosine kinase (BTK) inhibitor or anti programmed cell death1 (PD1)/antiProgrammed Death Ligand1 (PDL1) treatment. History of interstitial lung disease or noninfectious pneumonitis except for those induced by radiation therapies Vaccination with a live vaccine within 28 days of the initiation of treatment. Participated in any investigational drug study within 28 days or not recovered from toxicity of any prior chemotherapy to grade ≤ 1. Major surgery in the past 4 weeks Active and symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus (HIV), human Tcell lymphotropic virus type 1 seropositive status Inability to comply with study procedures Pregnant or nursing women Men or women of childbearing potential who refuse to use an adequate measure of contraception unless they have past medical history of surgical sterilization. Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any study's endpoints</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>